PD-L1 testing and immunotherapy selection – early laboratory experience and its potential role in head and neck cancer management

Anti-programmed cell death protein-1 (PD-1) therapy has been relatively recently approved in a defined context by NICE in adults in the management of recurrent and metastatic head and neck squamous cell carcinomas (HNSCC). In this context, companion diagnostic programmed cell death ligand-1 (PD-L1)...

Descripción completa

Detalles Bibliográficos
Autores principales: Bancu, Andrei, Cowan, Richard, Chaturvedi, Anshuman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: UMF “Gr. T. Popa” Iasi Publishing House 2021
Materias:
Original Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565705/
https://www.ncbi.nlm.nih.gov/pubmed/34754934
http://dx.doi.org/10.22551/2021.30.0801.10179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565705/
https://www.ncbi.nlm.nih.gov/pubmed/34754934
http://dx.doi.org/10.22551/2021.30.0801.10179

Ejemplares similares